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Introduction {#ehf212351-sec-0005}
============

In 2002, Silverberg *et al*. first described the term cardiorenal anaemia syndrome (CRAS).[1](#ehf212351-bib-0001){ref-type="ref"} The term CRAS is widely used in recent years after understanding the importance and association between heart failure (HF), renal failure, and anaemia. It has been demonstrated that any of the above‐mentioned three conditions can contribute to the development and worsening of the other two conditions. Hence, the proper understanding of its significance and association is important in the management of CRAS patients.[2](#ehf212351-bib-0002){ref-type="ref"}

The role of CRAS in acute HF (AHF) is scarcely investigated as almost all the previous studies were performed on chronic HF (CHF) patients. The prevalence of CRAS in HF ranges between 19% and 62%.[3](#ehf212351-bib-0003){ref-type="ref"} In CHF, patients with CRAS have been associated with higher mortality than patients without CRAS.[4](#ehf212351-bib-0004){ref-type="ref"} There are currently no data available on AHF and CRAS in the Arabian Gulf region. Hence, the aim of this study was to evaluate the incidence and impact of CRAS on all‐cause mortality in AHF patients stratified by left ventricular ejection fraction (LVEF) in the Middle East.

Methods {#ehf212351-sec-0006}
=======

Gulf CARE is a prospective, multinational, multicentre registry of patients admitted with the diagnosis of AHF to 47 hospitals in seven Middle Eastern countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, and Yemen). The registry design, methods, and collected clinical variables have been described elsewhere.[5](#ehf212351-bib-0005){ref-type="ref"} Briefly, men and women ≥ 18 year of age, admitted (from 14 February 2012 to 14 November 2012) to the participating hospitals with an admission diagnosis of AHF, were recruited. Baseline and admission‐based variables captured data on demographic, co‐morbidities, behavioural risk factors, clinical presentation, investigations, including medication history, and in‐hospital outcomes. Follow‐up for all‐cause mortality was carried out telephonically at 3 months and either telephonically or through outpatient clinic visits at 1 year.

Data entry was carried out online using a custom‐designed electronic case‐record form (CRF) at the Gulf CARE website ([www.gulfcare.org](http://www.gulfcare.org)). The study complies with the Declaration of Helsinki. Institutional or national ethics committee or review board approvals were obtained from each of the seven participating countries. The study was registered at [clinicaltrials.gov](http://clinicaltrials.gov) (NCT01467973).

AHF was defined on the basis of the European Society of Cardiology (ESC) criteria.[6](#ehf212351-bib-0006){ref-type="ref"} Definitions of data variables in the CRF were based on the 2008 ESC guidelines and the American College of Cardiology clinical data standards.[7](#ehf212351-bib-0007){ref-type="ref"} Khat chewing was defined as chewing khat plant/leaves (*Catha edulis* containing cathinone, an amphetamine‐like stimulant that can cause euphoria, hypertension, myocardial infarction, and dilated cardiomyopathy)[8](#ehf212351-bib-0008){ref-type="ref"} within 1 month of the index admission. Presence of documented chronic kidney disease (CKD) was defined as estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m^2^ or serum creatinine levels \>177 mmol/L (or 2 mg/dL) for at least 3 months as well as the presence of renal dysfunction (serum creatinine \>2 mg/dL) in the setting of acute *de novo* HF or in patients with unknown history of kidney disease. Anaemia was defined as haemoglobin levels of \<12 g/dL in women and \<13 g/dL in men. CRAS was defined as the condition where HF, CKD, and anaemia coexist.[1](#ehf212351-bib-0001){ref-type="ref"} HF with *preserved* ejection fraction (HF*p*EF) was defined as those with LVEF of ≥50%, while HF with *reduced* ejection fraction (HF*r*EF) was defined as those patients with LVEF of \<50%.[6](#ehf212351-bib-0006){ref-type="ref"}

Statistical analysis {#ehf212351-sec-0007}
--------------------

Descriptive statistics were used to summarize the data. For categorical variables, frequencies and percentages were reported. Differences between groups were analysed using Pearson\'s *χ* ^2^ test. For continuous variables, mean and standard deviation were used to summarize the data while analysis was performed using Student\'s *t*‐test.

Multivariable logistic regression models were performed to evaluate the impact of CRAS on all‐cause mortality (primary outcome) at in‐hospital and at 3 and at 12 months post‐hospital discharge stratified by LVEF status. In total, there were three models for each time period: Model 1 was for all patients, and the other two models were stratified by LVEF (HF*p*EF and HF*r*EF groups) separately. Multivariate analyses were conducted using logistic regression models utilizing the simultaneous method. For the in‐hospital mortality, the model was adjusted for age, gender, body mass index, smoking, khat chewing, peripheral vascular disease (PVD), hypertension, diabetes mellitus, prior stroke/transient ischaemic attack, first admission haemoglobin, systolic blood pressure (BP), diastolic BP, LVEF, serum creatinine, in‐hospital percutaneous coronary intervention or coronary artery bypass graft, in‐hospital course \[including non‐invasive ventilation, intubation/ventilation, cardiogenic shock, inotropes, intra‐aortic balloon pump, acute dialysis/ultrafiltration, atrial fibrillation (AF) requiring therapy, major bleeding, blood transfusion, stroke, and systemic infection requiring therapy\], intravenous (bolus) furosemide during admission and prior medication use \[diuretics, digoxin, oral nitrates, calcium channel blockers (CCBs), beta‐blockers, aldosterone antagonist, angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blocker (ARBs), aspirin, and clopidogrel\]. For the 3 and 12 months\' mortality, the models were adjusted for variables just like in the in‐hospital mortality model, except for the fact that instead of the prior medications, they included discharged medications (diuretics, digoxin, oral nitrates, CCBs, beta‐blockers, aldosterone antagonist, ACE inhibitors, ARBs, aspirin, and clopidogrel). Furthermore, in‐hospital course was also removed from the models at 3 and 12 months.

The goodness of fit of the multivariable logistic model was examined using the Hosmer and Lemeshow goodness‐of‐fit statistic.[9](#ehf212351-bib-0009){ref-type="ref"} Based on the *χ* ^2^ distribution, a Hosmer and Lemeshow statistic with a *P* \> 0.05 is considered a good fit. The discriminatory power of the logistic model was assessed by the area under the receiver operating characteristic (ROC) curve, also known as the *C*‐index.[10](#ehf212351-bib-0010){ref-type="ref"} A model with perfect discriminative ability has a *C*‐index of 1.0; an index of 0.5 provides no better discrimination than chance. Models with area under the ROC curve of \>0.7 are preferred. An *a priori* two‐tailed level of significance was set at *P* \< 0.05. Statistical analyses were conducted using STATA Version 13.1 (STATA Corporation, College Station, TX, USA).

Results {#ehf212351-sec-0008}
=======

The analysed cohort consisted of 4934 patients, after removing 71 subjects (1.4%) who had missing anaemia and eGFR. The overall mean age of the cohort was 59 ± 15 years in which 62% (*n* = 3081) were men. Fifty‐four per cent of the patients (*n* = 2683) presented with acute decompensated CHF (ADCHF) with the mean LVEF of 37 ± 14%. Co‐morbid conditions were common in this cohort particularly hypertension (*n* = 3014; 61%), coronary artery disease (CAD; *n* = 2971; 60%), diabetes mellitus (*n* = 2449; 50%), and hyperlipidaemia (*n* = 1770; 36%), and 79% (*n* = 3576) had HF*r*EF. The rest of the demographic and clinical variables are shown in *Table* [1](#ehf212351-tbl-0001){ref-type="table"}.

###### 

Demographic and clinical characteristics of the cohort stratified by cardiorenal anaemia syndrome status among patients with acute heart failure

  Characteristic, n (%) unless specified otherwise            All (*n* = 4934)   CRAS         *P*‐value    
  ----------------------------------------------------------- ------------------ ------------ ------------ ---------
  Demographic                                                                                              
  Age, mean ± SD, years                                       59 ± 15            57 ± 15      65 ± 14      \<0.001
  Male gender                                                 3081 (62%)         2378 (66%)   703 (53%)    \<0.001
  BMI, mean ± SD, kg/m^2^                                     28.1 ± 6.3         27.8 ± 6.0   29.1 ± 7.0   \<0.001
  Smoking                                                     1076 (22%)         912 (25%)    164 (12%)    \<0.001
  Khat                                                        886 (18%)          738 (20%)    148 (11%)    \<0.001
  Alcohol                                                     175 (3.6%)         152 (4.2%)   23 (1.7%)    \<0.001
  Medical history                                                                                          
  Hyperlipidaemia                                             1770 (36%)         1126 (31%)   644 (49%)    \<0.001
  CAD                                                         2971 (60%)         2107 (58%)   864 (66%)    \<0.001
  Hypertension                                                3014 (61%)         1992 (55%)   1022 (77%)   \<0.001
  Diabetes mellitus                                           2449 (50%)         1560 (43%)   889 (67%)    \<0.001
  PVD                                                         208 (4.2%)         102 (2.8%)   106 (8.0%)   \<0.001
  Stroke/TIA                                                  399 (8.1%)         231 (6.4%)   168 (13%)    \<0.001
  AF                                                          594 (12%)          408 (11%)    186 (14%)    0.007
  CKD/dialysis                                                740 (15%)          219 (6.1%)   521 (40%)    \<0.001
  Clinical parameters at presentation                                                                      
  HR, mean ± SD, b.p.m.                                       78 ± 13            78 ± 12      76 ± 14      \<0.001
  SBP, mean ± SD, mmHg                                        138 ± 34           137 ± 34     141 ± 34     \<0.001
  DBP, mean ± SD, mmHg                                        81 ± 20            82 ± 20      79 ± 19      \<0.001
  Crea, mean ± SD, μmol/L                                     128 ± 110          99 ± 64      207 ± 159    \<0.001
  LVEF, mean ± SD, %                                          37 ± 14            36 ± 14      38 ± 14      0.017
  Hg, mean ± SD, g/dL                                         12.6 ± 2.4         13.4 ± 2.2   10.4 ± 1.5   \<0.001
  In‐hospital course                                                                                       
  PCI/CABG                                                    353 (7.2%)         303 (8.4%)   50 (3.8%)    \<0.001
  Treatment course[a](#ehf212351-note-0003){ref-type="fn"}    2224 (45%)         1519 (42%)   705 (53%)    \<0.001
  Admission diagnosis                                                                                      
  *De novo* AHF                                               2251 (46%)         1805 (50%)   446 (34%)    \<0.001
  ADCHF                                                       2683 (54%)         1810 (50%)   873 (66%)    
  NYHA at discharge[b](#ehf212351-note-0004){ref-type="fn"}                                                
  I                                                           2423 (52%)         1892 (55%)   531 (44%)    
  II                                                          1837 (40%)         1261 (37%)   576 (48%)    \<0.001
  III                                                         145 (3.1%)         103 (3.0%)   42 (3.5%)    
  IV                                                          221 (4.8%)         170 (5.0%)   51 (4.3%)    

ADCHF, acute decompensated chronic heart failure; AF, atrial fibrillation; AHF, acute heart failure; b.p.m., beats per minute; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; Crea, first serum creatinine; CRAS, cardiorenal anaemia syndrome; DBP, diastolic blood pressure; Hg, first haemoglobin on admission; HR, heart rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischaemic attack.

CRAS was defined as estimated glomerular filtration rate of \<60 mL/min and haemoglobin of \<13 g/dL for men or \<12 g/dL for women. HR was missing in 202 subjects, SBP and DBP in 155, and LVEF in 426. Percentages might not add up to 100% owing to rounding off.

Treatment course included non‐invasive ventilation, intubation/ventilation, cardiogenic shock, inotropes, intra‐aortic balloon pump, acute dialysis/ultrafiltration, atrial fibrillation requiring therapy, major bleeding, blood transfusion, stroke, and systemic infection requiring therapy.

Last NYHA classification excluded those who died in‐hospital (*n* = 308).

A total of 27% (*n* = 1319) of the AHF patients had CRAS. CRAS patients were older (65 vs. 57 years; *P* \< 0.001) and more likely to be obese (29.1 vs. 27.8 kg/m^2^; *P* \< 0.001); presented with higher rates of hyperlipidaemia (49% vs. 31%; *P* \< 0.001), CAD (66% vs. 58%; *P* \< 0.001), hypertension (77% vs. 55%; *P* \< 0.001), diabetes mellitus (67% vs. 43%; *P* \< 0.001), stroke/transient ischaemic attack (13% vs. 6.4%; *P* \< 0.001), PVD (8.0% vs. 2.8%; *P* \< 0.001), AF (14% vs. 11%; *P* = 0.007), CKD/dialysis (40% vs. 6.1%; *P* \< 0.001), and lower admission haemoglobin levels (10.4 vs. 13.4 g/dL; *P* \< 0.001). The CRAS group was more likely to have treatment course during hospital admission (53% vs. 42%; *P* \< 0.001). The CRAS cohort was also more likely to be associated with ADCHF than were those who did not have CRAS (66% vs. 50%; *P* \< 0.001) (*Table* [1](#ehf212351-tbl-0001){ref-type="table"}).

The majority of the patients were on standard HF therapy. Intake of digoxin prior to the admission was found almost similar in both groups (16% vs. 17%; *P* = 0.600). ACE inhibitors were the only medication type that the non‐CRAS group used more than did the CRAS cohort (44% vs. 38%; *P* \< 0.001), and this persisted even during discharge. Use of beta‐blockers (72% vs. 66%; *P* \< 0.001) and aldosterone antagonist (48% vs. 31%; *P* \< 0.001) was more in the non‐CRAS group compared with the CRAS group (*Table* [2](#ehf212351-tbl-0002){ref-type="table"}).

###### 

Medication utilization of the cohort stratified by cardiorenal anaemia syndrome status among patients with acute heart failure

  Characteristic, n (%) unless specified otherwise                              All (*n* = 4934)   CRAS         *P*‐value    
  ----------------------------------------------------------------------------- ------------------ ------------ ------------ ---------
  Prior medications                                                                                                          
  Diuretics                                                                     2834 (57%)         1921 (53%)   913 (69%)    \<0.001
  Digoxin                                                                       819 (17%)          594 (16%)    225 (17%)    0.600
  Oral nitrates                                                                 1265 (26%)         795 (22%)    470 (36%)    \<0.001
  CCBs                                                                          655 (13%)          338 (9.4%)   317 (24%)    \<0.001
  ACE inhibitors                                                                2097 (43%)         1592 (44%)   505 (38%)    \<0.001
  ARBs                                                                          628 (13%)          403 (11%)    225 (17%)    \<0.001
  Statins                                                                       2519 (51%)         1687 (47%)   832 (63%)    \<0.001
  Aspirin                                                                       3037 (62%)         2115 (59%)   922 (70%)    \<0.001
  Ivabradine                                                                    115 (2.3%)         70 (1.9%)    45 (3.4%)    0.002
  Beta‐blockers                                                                 2155 (44%)         1500 (41%)   655 (50%)    \<0.001
  Aldosterone antagonists                                                       822 (17%)          595 (16%)    227 (17%)    0.531
  Intravenous (IV) medications during admission                                                                              
  IV furosemide---bolus                                                         4482 (91%)         3271 (90%)   1211 (92%)   0.152
  IV furosemide---infusion                                                      856 (17%)          559 (15%)    297 (23%)    \<0.001
  IV nitrates---infusion                                                        997 (20%)          706 (20%)    291 (22%)    0.050
  Discharged medications (*n* = 4626)[a](#ehf212351-note-0007){ref-type="fn"}                                                
  Diuretics                                                                     4340 (94%)         3213 (94%)   1127 (94%)   0.868
  Digoxin                                                                       1153 (25%)         893 (26%)    260 (22%)    0.002
  Oral nitrates                                                                 1757 (38%)         1185 (35%)   572 (48%)    \<0.001
  CCBs                                                                          727 (16%)          390 (11%)    337 (28%)    \<0.001
  ACE‐I                                                                         2812 (61%)         2287 (67%)   525 (44%)    \<0.001
  ARBs                                                                          775 (17%)          562 (16%)    213 (18%)    0.283
  Statins                                                                       3348 (72%)         2433 (71%)   915 (76%)    \<0.001
  Aspirin                                                                       3741 (81%)         2777 (81%)   964 (80%)    0.584
  Ivabradine                                                                    238 (5.1%)         163 (4.8%)   75 (6.3%)    0.044
  Beta‐blockers                                                                 3262 (71%)         2469 (72%)   793 (66%)    \<0.001
  Aldosterone antagonists                                                       2002 (43%)         1629 (48%)   373 (31%)    \<0.001

ACE, angiotensin‐converting enzyme; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; CRAS, cardiorenal anaemia syndrome.

CRAS was defined as estimated glomerular filtration rate of \<60 mL/min and haemoglobin of \<13 g/dL for men or \<12 g/dL for women. Percentages might not add up to 100% owing to rounding off.

Medications at discharged only included those who were discharged alive from the hospital and did not leave against medical advice (*n* = 4626).

The overall cumulative all‐cause mortality at in‐hospital, 3 months, and 1 year was 5.1% (*n* = 231), 11.6% (*n* = 521), and 19.2% (*n* = 867), respectively. After adjusting for demographic and clinical characteristics as well as medication use in the overall multivariate logistic regression models (*Table* [3](#ehf212351-tbl-0003){ref-type="table"}), the CRAS group was associated with higher odds of all‐cause mortality during admission \[adjusted odds ratio (aOR), 2.10; 95% confidence interval (CI): 1.34--3.31; *P* = 0.001\], at 3 months\' follow‐up (aOR, 1.48; 95% CI: 1.07--2.06; *P* = 0.018), and at 12 months\' follow‐up (aOR, 1.45; 95% CI: 1.12--1.87; *P* = 0.004).

###### 

Impact of cardiorenal anaemia syndrome status on mortality (at in‐hospital, at 3 months, and at 12 months) of the Gulf CARE cohort stratified by left ventricular ejection fraction status

  Mortality               Pearson\'s *χ* ^2^ test   Multivariate logistic regression                                                                   
  ----------------------- ------------------------- ---------------------------------- ------------- --------- --------------------- ------- --------- ------
  In‐hospital                                                                                                                                          
  All patients            231 (5.1%)                132 (4.0%)                         99 (8.3%)     \<0.001   2.10 \[1.34--3.31\]   0.001   0.175     0.87
  HF*p*EF (LVEF ≥ 50%)    53 (5.7%)                 33 (5.1%)                          20 (7.1%)     0.222     2.15 \[0.84--5.55\]   0.113   \<0.001   0.85
  HF*r*EF (LVEF \< 50%)   178 (5.0%)                99 (3.7%)                          79 (8.7%)     \<0.001   2.03 \[1.20--3.45\]   0.009   0.311     0.87
  3 months                                                                                                                                             
  All patients            521 (11.6%)               322 (9.7%)                         199 (16.7%)   \<0.001   1.48 \[1.07--2.06\]   0.018   \<0.001   0.77
  HF*p*EF (LVEF ≥ 50%)    115 (12.3%)               74 (11.4%)                         41 (14.5%)    0.179     1.87 \[0.93--3.76\]   0.078   0.096     0.79
  HF*r*EF (LVEF \< 50%)   406 (11.4%)               248 (9.3%)                         158 (17.4%)   \<0.001   1.43 \[0.98--2.09\]   0.063   0.005     0.77
  12 months                                                                                                                                            
  All patients            867 (19.2%)               545 (16.4%)                        322 (27.1%)   \<0.001   1.45 \[1.12--1.87\]   0.004   0.008     0.74
  HF*p*EF (LVEF ≥ 50%)    181 (19.4%)               114 (17.5%)                        67 (23.8%)    0.027     1.59 \[0.91--2.76\]   0.101   0.742     0.74
  HF*r*EF (LVEF \< 50%)   686 (19.2%)               431 (16.2%)                        255 (28.1%)   \<0.001   1.42 \[1.06--1.89\]   0.019   0.022     0.74

ACE, angiotensin‐converting enzyme; Adj. OR, adjusted odds ratio; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; CI, confidence interval; CRAS, cardiorenal anaemia syndrome; HF*p*EF, heart failure with *preserved* ejection fraction; HF*r*EF, heart failure with *reserved* ejection fraction; HL, Hosmer and Lemeshow *P*‐value; LVEF, left ventricular ejection fraction; ROC, area under the receiver operating characteristic curve, also known as *C*‐statistic.

CRAS was defined as estimated glomerular filtration rate of \<60 mL/min and haemoglobin of \<13 g/dL for men or \<12 g/dL for women. Per cents are row percentages. Multivariate analyses were conducted using logistic regression models utilizing the simultaneous method. For the in‐hospital mortality, the model adjusted for age, gender, body mass index, smoking, khat chewing, peripheral vascular disease, hypertension, diabetes mellitus, prior stroke/transient ischaemic attack, systolic blood pressure, diastolic blood pressure, LVEF, serum creatinine, in‐hospital percutaneous coronary intervention or coronary artery bypass graft, in‐hospital course (including non‐invasive ventilation, intubation/ventilation, cardiogenic shock, inotropes, intra‐aortic balloon pump, acute dialysis/ultrafiltration, atrial fibrillation requiring therapy, major bleeding, blood transfusion, stroke, and systemic infection requiring therapy), prior medication use \[diuretics, digoxin, oral nitrates, CCBs, beta‐blockers, aldosterone antagonist, ACE inhibitors, ARBs, aspirin, I~f~ channel blocker (ivabradine)\], intravenous (bolus) furosemide during admission, admission diagnosis (acute decompensated chronic heart failure or acute heart failure), and New York Heart Association functional class. For the 3 and 12 months\' mortality, the models adjusted for variables just like in the in‐hospital mortality model, except for the fact that instead of the prior medications, they included discharged medications \[diuretics, digoxin, oral nitrates, CCBs, beta‐blockers, aldosterone antagonist, ACE inhibitors, ARBs, aspirin, and I~f~ channel blocker (ivabradine)\]. From an original discharged cohort of 4934 (excluding those who died in‐hospital and left against medical advice), lost to follow‐up reached a total of 1.5% (*n* = 75) at 3 months and still remained at 1.5% (*n* = 75) at 1 year. However, as the analysis was stratified by LVEF, this excluded those who had missing LVEF (*n* = 426) on admission, leaving the analysable cohort of 4508.

It was in those patients with HF*r*EF, when stratified by LVEF, that CRAS was associated with higher odds of all‐cause mortality during hospital admission (aOR, 2.03; 95% CI: 1.20--3.45; *P* = 0.009) and at 12 months\' follow‐up (aOR, 1.42; 95% CI: 1.06--1.89; *P* = 0.019) but not at 3 months\' follow‐up (aOR, 1.43; 95% CI: 0.98--2.09; *P* = 0.063). In those patients with HF*p*EF, CRAS was not associated with higher odds of all‐cause mortality during hospital admission (aOR, 2.15; 95% CI: 0.84--5.55; *P* = 0.113), at 3 months\' follow‐up (aOR, 1.87; 95% CI: 0.93--3.76; *P* = 0.078), or at 12 months\' follow‐up (aOR, 1.59; 95% CI: 0.91--2.76; *P* = 0.101).

Of note, there were a total of 39 (0.8%) events of major bleeds in the cohort with the CRAS group more likely to be associated with major bleeds (1.3 vs. 0.6%; *P* = 0.017). The CRAS cohort was also more likely to be associated with the utilization of blood transfusion between the groups (10.8 vs. 3.0%; *P* \< 0.001). Additionally, the CRAS group was also more likely to be associated with higher rates of hospitalization for HF at 3 months (27.6% vs. 18.8%; *P* \< 0.001) and at 12 months (34.3% vs. 26.2%; *P* \< 0.001).

Discussion {#ehf212351-sec-0009}
==========

This is among the first cardiorenal anaemia syndrome studies in AHF patients in the Middle East. In this cohort of AHF patients, 27% had CRAS, which was also associated with worse all‐cause mortality during in‐hospital, at 3 months\' follow‐up, and at 12 months\' follow‐up, than in AHF patients who did not have CRAS, especially in those patients with HF*r*EF.

Incidence of CRAS varies from 3% to 44.4%.[11](#ehf212351-bib-0011){ref-type="ref"}, [12](#ehf212351-bib-0012){ref-type="ref"}, [13](#ehf212351-bib-0013){ref-type="ref"}, [14](#ehf212351-bib-0014){ref-type="ref"} In Candesartan in Heart Failure---Assessment of Reduction in Mortality and Morbidity (CHARM) trial, 14% (371/2653) of the patients were identified to have CRAS.[11](#ehf212351-bib-0011){ref-type="ref"} From a Canadian population‐based study of new onset HF, 3% (362/12 065) of the patients had CRAS.[12](#ehf212351-bib-0012){ref-type="ref"} In a small Tanzanian study, they found that 44% (202/455) of the patients had CRAS.[13](#ehf212351-bib-0013){ref-type="ref"} In another study, 22% (210/955) of the patients had CRAS.[14](#ehf212351-bib-0014){ref-type="ref"} In our study, we found that \~27% patient population comes under the CRAS category, which is almost double the results we obtained from CHARM trial. We hypothesize that this may be due to differences in ethnicity.

Over the past two decades, the medical community is curiously investigating and initiating various research registries for the CRAS population. In the ATTEND registry, CRAS patients were considered as high‐risk category relative to patients without anaemia or renal dysfunction. CRAS in patients at discharge was an independent predictor of re‐admission for HF and mortality.[15](#ehf212351-bib-0015){ref-type="ref"}, [16](#ehf212351-bib-0016){ref-type="ref"} Review of literature shows CRAS patients were associated with higher mortality.[17](#ehf212351-bib-0017){ref-type="ref"} Left ventricular dysfunction and renal dysfunction are independent predictors of poor prognosis and higher mortality.[18](#ehf212351-bib-0018){ref-type="ref"} In a single‐centred study, it was shown that, along with anaemia in AHF patients, a high red blood cell distribution width was associated with higher all‐cause mortality.[19](#ehf212351-bib-0019){ref-type="ref"}

Literature review shows that in the European Society of Cardiology---Heart Failure (ESC‐HF) pilot registry, 26% (1300/5000) of AHF patients had CKD. In Acute Decompensated Heart Failure National Registry (ADHERE), 64% (76 800/120 000) of the patients had CKD.[20](#ehf212351-bib-0020){ref-type="ref"}, [21](#ehf212351-bib-0021){ref-type="ref"} In our study, CKD was present in 44% patients, which comes between the ESC‐HF and ADHERE results.

Anaemia was found in 31% (1550/5000) of the patients of (ESC‐HF) pilot registry, 40% (48 000/120 000) of the patients in ADHERE registry, 37% (55 500/150 000) of the patients in a meta‐analysis of 34 trials, and 33% of the patients in the EuroHeart Failure Survey.[22](#ehf212351-bib-0022){ref-type="ref"}, [23](#ehf212351-bib-0023){ref-type="ref"}, [24](#ehf212351-bib-0024){ref-type="ref"}, [25](#ehf212351-bib-0025){ref-type="ref"} In a small study of 142 CHF patients who visited the outpatient clinic, 55.6% of patients had anaemia.[26](#ehf212351-bib-0026){ref-type="ref"}, [27](#ehf212351-bib-0027){ref-type="ref"} In our study, 48% of the patients had anaemia, which was slightly higher than that of all the previous major studies. Higher incidence of anaemia in our study may be due to the criteria used or due to regional variation.

The Framingham study did an analysis of CHF patients\' data from 1950 to 1959, which showed a 1 year mortality of 30%, and the adjusted data for mortality among CHF patients during 1990 to 1999 were 28%.[28](#ehf212351-bib-0028){ref-type="ref"} In a cohort of 1 136 201 patients from the Medicare database, an annual mortality of 23% (261 326/1 136 201) in patients with CRAS was shown. If you compare 2 year mortality, then the probability will rise to 300%.[29](#ehf212351-bib-0029){ref-type="ref"} In an Australian study, patients had greater all‐cause mortality, which is 55% (411/748).[4](#ehf212351-bib-0004){ref-type="ref"} In our study, the overall mortality at in‐hospital, 3 months, and 12 months was higher with the CRAS group.

The limitation of this study is its nature of being a registry, which may have introduced bias through confounding by variables not controlled for or measured (such as iron levels and history of chronic anaemia). This study is a sub‐analysis of an observational study, which is like any observational study, where the possibility for unmeasured confounding variables exists. In some countries, only a few hospitals took part in the registry; hence, the results are not entirely generalizable. Reasons for underuse of medications or procedures were not known in this study. The recording of natriuretic peptides was optional as not all countries routinely measure them. Echocardiographic interpretation was at the discretion of the person performing the study; no centralized evaluation was performed. Patients\' renal function at discharge is unknown, and there are no data regarding the frequency of patients with improvement of renal function. This study did not record the cognitive status and the disability status in patients with stroke, which obviously have a major impact on morbidity and mortality and only 1 year mortality. Mortality rates at follow‐up were only recorded at 1 year without the specification of the exact date of death of each patient, and hence, the Kaplan--Meier curves could not have been performed. Finally, no information was available regarding the cause of stroke. Future studies need to overcome these limitations.

Conclusions {#ehf212351-sec-0010}
===========

In conclusion, the incidence of cardiorenal anaemia syndrome in AHF in the Arabian Gulf citizens was 27%. CRAS was associated with worse short‐term and long‐term all‐cause cumulative mortality in AHF patients, especially in those with HF*r*EF.
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